A RANDOMISED CONTROL TRIAL ON CEREBRO VASCULAR ACCIDENT PATIENTS WITH REFERENCE TO AETIOLOGY AND MANAGEMENT: 24 WEEKS, SINGLE-CENTER, PROSPECTIVE OBSERVATIONAL PILOT STUDY
Objectives: Stroke is one of the leading causes of death and long-term disability in world. Stroke is an important cause of premature death and disability in low-income and middle-income countries like India, largely driven by demographic changes and enhanced by the increasing prevalence of key modifiable risk factors. The main aim of our study was to assess the clinical profile with special reference to the etiology of the condition, the management, and drug utilization review.
Methods: This is a hospital-based prospective observational randomized control trial which was conducted for a period of 6 months at Government General Hospital, Rajiv Gandhi Institute of Medical Sciences, Kadapa. Seventy-five patients were recruited based on study criteria. The data were analyzed and summarized as frequency and percentage by GraphPad Prism software using Microsoft Excel.
Results: In a total of 75 patients, it was found that 45 and 30 patients were female. Maximum number of patients (i.e. 36 patients) belonged to 51–60 years age group. We observed that 52 patients were suffering from ischemic stroke, 21 patients were suffering from transient ischemic stroke, and only 2 patients were suffering from ischemic stroke and transient ischemic stroke. Among 75 patients studied, hypertension (62%), diabetes mellitus (28%), smoking (33%), and alcohol (33%) were the risk factors.
Conclusion: In this study, ischemic stroke was most prevalent. Hypertension, that is, increase of blood pressure considered as one of the important and major risk factors for stroke occurrence and recurrence. Proper management includes non-pharmacological (physiotherapy) along with pharmacological treatment that included cardiovascular system drugs such as hypolipidemics, cognition enhancers, anticoagulants, and antihypertensive therapy.
2. Yang Q, Tong X, Schieb L, Vaughan A, Gillespie C, Wiltz JL, et al. Vital signs: Recent trends in stroke death rates-United States, 2000- 2015. MMWR Morb Mortal Wkly Rep 2017;66:933-9.
3. Bushnell C, McCullough LD, Awad IA, Chireau MV, Fedder WN, Furie KL, et al. Guidelines for the prevention of stroke in women. Stroke 2014;45:1545-88.
4. National Institute of Neurological Disorders and Stroke rt-PA Stroke Study Group. Tissue plasminogen activator for acute ischemic stroke. N Engl J Med 1995;33:1581-7.
5. Ohara T, Uehara T, Sato S, Hayakawa M, Kimura K, Okada Y, et al. A small vessel occlusion is a high-risk etiology for early recurrent stroke after transient ischemic attack. Int J Stroke 2019;14:871-7.
6. Babtain F, Bhatia H, Al Shehri E, Al Ghamdi B, Al Amer E, Al Jabri M, et al. Stroke etiology varies with age in patients younger than 50 years: Assessment of stroke etiology and classifications in young Saudi patients. Am J Med Med Sci 2014;4:14-8.
7. Fathima M, Najeeb S, Fatima S, Khalid SM, Nikhat SR, Rao RC. A prospective observational study on risk factors and management of stroke at a tertiary care teaching hospital. Int J Pharm Pharm Sci 2018;10:45-9.
8. Mergenthaler P, Dirnagl U, Meisel A. Pathophysiology of stroke: Lessons from animal models. Metab Brain Dis 2004;19:151-67.
9. Jan R, Gupta RK, Singh P, Shora T, Hussain S. Risk factors for stroke: A hospital based descriptive study in North India. Int J Stroke Res 2015;3:1-5.
10. Zhang L, Zhang ZG, Zhang RL, Lu M, Krams M, Chopp M. Effects of a selective cd11b/cd18 antagonist and recombinant human tissue plasminogen activator treatment alone and in combination in a rat embolic model of stroke. Stroke 2003;34:1790-5.
11. Sobolewski P, Brola W, Szczuchniak W, Fudala M, Kozera G. Intravenous thrombolysis with recombinant tissue-type plasminogen activator for acute ischemic stroke in patients with metabolic syndrome. J Stroke Cerebrovasc Dis 2015;24:1787-92.
12. Thang S, Christopher Henry, David Fluck, Brendan Affley, Giosue Gulli, Christopher Barrett, et al. Anticoagulation therapy in patients with stroke and atrial fibrillation: A registry-based study of acute stroke care in surrey, UK. Ann J Med 2018;2:14-26.
13. Lau KK, Lovelock CE, Li L, Simoni M, Gutnikov S, Küker W, et al. Antiplatelet treatment after transient ischemic attack and ischemic stroke in patients with cerebral microbleeds in 2 large cohorts and an updated systematic review. Stroke 2018;49:1434-42.
14. Cimino M, Balduini W, Carloni S, Gelosa P, Guerrini U, Tremoli E, et al. Neuroprotective effect of simvastatin in stroke: A comparison between adult and neonatal rat models of cerebral ischemia. Neurotoxicology 2005;26:929-33.
15. Makihara N, Kamouchi M, Hata J, Matsuo R, Ago T, Kuroda J, et al. Statins and the risks of stroke recurrence and death after ischemic stroke: The Fukuoka stroke registry. Atherosclerosis 2013;231:211-5.
16. Schurr A. Neuroprotection against ischemic/hypoxic brain damage: Blockers of ionotropic glutamate receptor and voltage sensitive calcium channels. Curr Drug Targets 2004;5:603-18.
17. Roumie CL, Zillich AJ, Bravata DM, Jaynes HA, Myers LJ, Yoder J, et al. Hypertension treatment intensification among stroke survivors with uncontrolled blood pressure. Stroke 2015;46:465-70.
18. Adams HP Jr., Adams RJ, Brott T, del Zoppo GJ, Furlan A, Goldstein LB, et al. A stroke council of the American stroke association: Guidelines for the early management of patients with ischemic stroke: A scientific statement from the stroke council of the American stroke association. Stroke 2003;34:1056-83.
19. Aboderin I, Venables G. Stroke management in Europe. Pan European Consensus Meeting on Stroke Management. J Intern Med 1996;240:173-80.
20. Becker K, Fruin M, Gooding T, Tirschwell D, Love P, Mankowski T. Community-based education improves stroke knowledge. Cerebrovasc Dis 2001;11:34-43.
21. European Federation of Neurological Societies Task Force, Brainin M. Neurological acute stroke care: The role of European neurology. Eur J Neurol 1997;4:435-41.
22. Marler JR, Tilley BC, Lu M, Brott TG, Lyden PC, Grotta JC, et al. Early stroke treatment associated with better outcome: The NINDS rt- PA stroke study. Neurology 2000;55:1649-55.
This work is licensed under a Creative Commons Attribution 4.0 International License.
The publication is licensed under CC By and is open access. Copyright is with author and allowed to retain publishing rights without restrictions.